Biosynth Exhibiting at Multiple Events in April 2024

Staad, Switzerland: – Microbiology and organic fine biochemical specialist manufacturer and developer Biosynth AG will be a presence at multiple pharmaceutical and cosmeceutical events in Europe and North America during April 2024.

Starting on April 16 in Paris, Biosynth will be exhibiting its chemistry, biology, peptide and biotech capabilities and huge catalog of high-quality materials at San Diego CA, Basel in Switzerland, and Boston MA, culminating in Amsterdam on May 1.

Varied events

The range of events attended is very varied, reflecting Biosynth’s highly diverse products and services range:

• In Cosmetics Global: A three-day event for the cosmeceuticals and personal care ingredients industry opening April 16 at the Paris Expo Porte de Versailles expo center in France, where Biosynth will be exhibiting from Booth 1D119 in Hall 1, represented by Evert van Dijik and Karim Vadiwala.
• San Diego Glycobiology Symposium: The SDGS conference brings together glycobiology researchers from the University of California and other California institutions to exchange information on the latest advances in the field. Biosynth is a  sponsor of this two-day event, which opens April 18 at the Alexandria Point in San Diego, with an event team that includes Sarah Kenny and Jessie Endicott.
• Swiss Biotech Day: One of Europe’s premier biotechnology conferences, Swiss Biotech Day is a 24-hour event opening April 22 at the Congress Center Basel, at the heart of Switzerland‘s biotechnology cluster. Biosynth is an associate sponsor of this conference that annually attracts more than 1,800 professionals from the global life sciences community for networking and knowledge sharing in R&D, manufacturing, data management, artificial intelligence, and innovative financing. Biosynth will also be an exhibitor at Booth 72, with a team led by Gerard Palau.
• Peptide Based Therapeutics Summit: Biosynth is also at inaugural Peptide Based Therapeutics Summit being staged as a three-day event opening April 23 at the Hilton Logan Airport in Boston, Massachusetts. The Summit has been founded to unite the pioneers in peptide-based drugs across diverse diseases and therapeutic approaches.
• 7th International Neoantigen Summit: Headlined as ‘Supercharging Neoantigen-Based Therapeutics & Cancer Vaccines Through Optimised Neoantigen Prediction & Streamlined Clinical Translation for Faster Approval’, this event returns to Amsterdam as a three-day event opening April 29 at the Hotel Novotel in the city center. The summit will reflect on significant progress in development of neoantigens as potential blockbuster therapies, featuring more than 20 eminent speakers, three workshop tracks exploring machine learning for target prediction, overcoming the immunosuppressive tumor microenvironment and optimized clinical trial design.

About Biosynth

Biosynth is a supplier of critical raw materials, and services for diagnostics, vaccines and pharmaceuticals with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation.

With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability spans Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner.  Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners, and management.

Find out more about Biosynth at www.biosynth.com

Resources

Click on Biosynth Events for further information and event links.
Click on Biosynth at In-Cosmetics Global to see exhibitor profile at event.
Click on Biosynth Videos to explore YouTube channel.